UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/533,090	04/29/2005	Norikazu Tabata	IPE-055	2293
Kubovcik & Ku	7590 10/16/200 1 <b>bovcik</b>	EXAMINER		
The Farragut Building Suite 710 900 17th Street, N.W. Washington, DC 20006			DICKINSON, PAUL W	
			ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			10/16/2008	PAPER

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
	10/533,090	TABATA ET AL.					
Office Action Summary	Examiner	Art Unit					
	PAUL DICKINSON	1618					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be timil apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 23 Ma	av 2008.						
	· · · · · · · · · · · · · · · · · · ·						
<i>,</i> —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-44</u> is/are pending in the application.							
• • • • • • • • • • • • • • • • • • • •	4a) Of the above claim(s) <u>11-33,36,38,39 and 41-44</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-10, 34, 35, 37 and 40</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or	· <u> </u>						
Application Papers							
9) ☐ The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  Paper No(s)/Mail Date							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date  Notice of Informal Patent Application							
Paper No(s)/Mail Date 6) Other:							

#### **DETAILED ACTION**

Applicant's arguments, filed 5/23/2008, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objects are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

### Response to Arguments

## Claim Rejections - 35 USC § 103

The rejection of Claims 1-10, 35, and 37 under 35 U.S.C. 103(a) as being unpatentable over WO 2001072280 (WO '280) in view of US 7160551 ('551) is maintained. The rejection of Claims 34 and 40 under 35 U.S.C. 103(a) as being unpatentable over WO 2001072280 (WO '280) in view of US 7160551 551) in further view of US 6586354 ('354) is maintained.

Applicant argues that the amended claims are limited to materials being soluble in dichloromethane, chloroform, ethyl acetate, isopropyl ether or a water miscible organic solvent, and the scope of the claim is therefore now limited to non-crosslinked materials. Applicant further argues that the crosslinked particles disclosed by WO '280 would not be able to (1) penetrate through a catheter and (2) maintain the form of a blood vessel without injuring the blood vessel.

Applicants arguments have been fully considered but are not found persuasive.

There is no requirement that the particles disclosed by WO '280 be crosslinked. WO

Art Unit: 1618

'280 teaches crosslinking as a means of adjusting the swellability of the particles, but no crosslinking may be necessary, and in fact WO '280 discloses examples, such as a copolymer of poly(lactic acid) with polyethylene glycol, which are not crosslinked. A copolymer of poly(lactic acid) with polyethylene glycol would inherently be soluble in the instantly claimed solvents (see instant specification, paragraph 178).

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., that the material must be able to (1) penetrate through a catheter and (2) maintain the form of a blood vessel without injuring the blood vessel) are not recited in the rejected claims. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). The particles disclosed by WO '280 are embolization materials, are degradable in a phosphate buffered saline of 37 °C, and are soluble in a water miscible organic solvents. The particles therefore meet the claim limitations.

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL DICKINSON whose telephone number is (571)270-3499. The examiner can normally be reached on Mon-Thurs 9:00am-6:30pm.

Application/Control Number: 10/533,090 Page 4

Art Unit: 1618

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618 Paul Dickinson Examiner AU 1618

October 10, 2008